Business Wire

SUMEC HARDWARE & TOOLS CO., LTD has obtained the Carbon Neutrality Certificate from TÜV Rheinland

Share

SUMEC HARDWARE & TOOLS CO. LTD, a leading manufacturer of gardening and tools equipment, has announced that it has received the first Certificate of Carbon Neutrality in the garden and tools industry by TÜV Rheinland. This recognition reinforces SUMEC's commitment to environmental sustainability, which has been a core value of the company since its inception.

TÜV Rheinland, a global leader in independent testing, inspection, and certification services, awarded the Certificate of Carbon Neutrality to SUMEC for its efforts to reduce its carbon footprint through a variety of measures. These include the implementation of energy-efficient practices, the use of renewable energy sources, and the adoption of sustainable materials in its products.

"We are extremely proud to receive this recognition from TÜV Rheinland," said Mr. Liu Kai, President of SUMEC HARDWARE & TOOLS CO. LTD. "Our commitment to environmental sustainability is a top priority for us, and we believe that it is our responsibility to contribute to the preservation of the planet. We are dedicated to reducing our carbon footprint, and we will continue to work towards a greener future for our customers and the planet."

SUMEC's carbon neutrality efforts include the implementation of solar energy systems at its manufacturing facilities, which has significantly reduced its carbon emissions. The company also uses sustainable materials in product designs of its own brand “Yard Force”, such as recycled plastics and natural fibers. SUMEC has also invested in energy-efficient equipment and practices, including LED lighting and smart energy management systems.

In addition to its carbon neutrality efforts, SUMEC is committed to reducing its overall environmental impact. The company has implemented a waste reduction program, which includes recycling initiatives and the reduction of packaging materials. SUMEC has also developed products with longer lifetimes, reducing the need for replacements and ultimately reducing waste.

"We believe that sustainability is not only important for the environment but also for the long-term success of our business," said Mr. Liu Kai. "By reducing our environmental impact, we are also reducing costs and improving the quality of products under our own brand ‘Yard Force’. We are committed to continuing our efforts to become an industry leader in sustainability."

SUMEC's achievement of the Certificate of Carbon Neutrality is a significant milestone for the company and the industry as a whole. It demonstrates that sustainable practices can be integrated into manufacturing and production processes, and that businesses can make a positive impact on the environment while still meeting customer demand.

As a company, SUMEC is dedicated to continuing its efforts towards environmental sustainability and hopes to inspire other businesses to do the same. The Certificate of Carbon Neutrality from TÜV Rheinland is a testament to the company's commitment to a greener future, and SUMEC looks forward to continuing to make a positive impact on the environment.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lin Yinlu / +86-13770517766

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

4P-Pharma Announces Total Capital of €15 Million Successfully Secured in Second Closing29.4.2024 07:40:00 EEST | Press release

4P-Pharma, a Lille-based clinical-stage startup studio focused on developing curative therapies for untreated serious diseases, announces that it has successfully secured a total capital of €15 million in its second closing with participation from private investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240424933193/en/ (Graphic: Business Wire) With this funding, 4P-Pharma's shareholders renew their confidence in the company's drug regeneration model for untreated serious diseases. They welcome the entry of Phase 2 clinical development of the two first 4P-Pharma's SPVs, underlying the robust potential of the company's business model. Revital Rattenbach, CEO of 4P-Pharma: "As CEO of 4P-Pharma, I am pleased with the renewed trust of our investors placed in our scientific and development approach year after year. This financial endorsement underscores our significant progress over the past decade. It attests to the str

PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA29.4.2024 07:17:00 EEST | Press release

PROTEINA announced today that it has held a kickoff meeting with Professor Janghee Woo and his research team at Emory University School of Medicine in Atlanta, to begin global clinical validation of its flagship product, PPI PathFinder BCL2 Dx. PPI PathFinder BCL2 Dx incorporates PROTEINA’s “SPID (Single-molecule Protein Interaction Detection)” technology, enabling high-sensitivity detection of protein-protein interaction (PPI) complexes of BCL2 family proteins and more accurate prediction of any PPI inhibitors targeting the BCL2 family. In this clinical validation, PPI PathFinder BCL2 Dx will be used to predict drug responsiveness in patients with Acute Myeloid Leukemia (AML), providing clinicians with guidance for more effective prescriptions of the widespread BCL2-targeted cancer drug “Venetoclax.” PROTEINA has previously conducted clinical validation of the same product domestically with the Hematologic Cancer Team at Seoul National University, and the findings are scheduled to be

TUM Races to Victory at ASPIRE’s Inaugural Abu Dhabi Autonomous Racing League at Yas Marina Circuit28.4.2024 14:57:00 EEST | Press release

TUM (Technical University of Munich) from Germany, claimed victory at the inaugural Abu Dhabi Autonomous Racing League (A2RL), at Yas Marina Circuit on Saturday (April 27). As the cars lined up on the grid, with antennae, sensors, AI capabilities, and drive-by-wire systems instead of human drivers, eight teams vied with one another over two days of races and challenges. TUM beat back the competition with its coding and engineering skills in a world-first, four-car race finale, to claim the winner’s share of US$2.25 million prize pot. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240428292385/en/ TUM Races to Victory at ASPIRE’s Inaugural Abu Dhabi Autonomous Racing League at Yas Marina Circuit - (Photo: AETOSWire) Bringing a science experiment to the racetrack, the inaugural race pushed the boundaries of autonomous technology while adding entertainment value to extreme sports at an unprecedented scale. A2RL drew over 10,000

ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 03:09:00 EEST | Press release

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio ha

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 23:06:00 EEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye